Alector, Inc.
Alector, Inc. (Nasdaq: ALEC) is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and Lewy body dementia. Its programs aim to remove pathogenic proteins, replace deficient proteins or restore cellular function, using… From the company’s description.
Over the twelve months to Sep 30, 2026, Alector, Inc. reported revenue of $173.47M, up 151.2% from a year earlier, and net income of $41.41M. Its operating margin was 20.2%, and operations used $149.88M in cash. In fiscal 2025, it reported revenue of $21.05M, down 79.1% from fiscal 2024, and a net loss of $142.93M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Alector, Inc. does
In the company’s own words
Alector, Inc. (Nasdaq: ALEC) is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and Lewy body dementia. Its programs aim to remove pathogenic proteins, replace deficient proteins or restore cellular function, using antibodies, enzymes and small interfering RNA (siRNA). Its lead clinical candidate, nivisnebart, is being co-developed with GlaxoSmithKline to elevate progranulin levels and is under evaluation in a Phase 2 trial for early Alzheimer’s disease. Alector’s proprietary Alector Brain Carrier (ABC) platform is designed to transport therapies across the blood-brain barrier; it supports preclinical programs including an anti-amyloid beta antibody, a GCase enzyme replacement therapy and siRNA candidates targeting tau, alpha-synuclein and NLRP3. The company’s portfolio is focused on research and development, with no approved drugs or commercial product sales. Its collaboration with GSK covers the development and potential commercialization of progranulin-elevating antibodies, while Alector retains wholly owned preclinical and research programs. Its website is https://www.alector.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1653087
- SIC
- 2836
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Alector, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Alector, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Alector, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Alector, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Alector, Inc.'s last four quarterly filings that the numbers alone won't show?”